Risk of breast cancer by type of menopausal hormone therapy: A case-control study among post-menopausal women in France

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Cordina Duverger, Emilie ^a,b   Truong, Thérèse ^a,b   Anger, Antoinette ^a,b   Sanchez, Marie ^a,b   Arveux, Patrick ^c   Kerbrat, Pierre ^d   Guénel, Pascal ^a,b  

^a INSERM   (France)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

^d CENTRE EUGÈNE MARQUIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN PLUS NATURAL PROGESTERONE; ESTROGEN PLUS PROGESTAGEN; ESTROGEN PLUS PROGESTERONE DERIVATIVE; ESTROGEN PLUS SYNTHETIC PROGESTAGEN; ESTROGEN PLUS TESTOSTERONE DERIVATIVE; GESTAGEN; HORMONE; NATURAL MICRONIZED PROGESTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TESTOSTERONE DERIVED PROGESTAGEN; TIBOLONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG FORMULATION; FEMALE; FRANCE; HORMONE SUBSTITUTION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MENOPAUSAL HORMONE THERAPY; MENOPAUSE; MIDDLE AGED; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; RISK ASSESSMENT; RISK FACTOR; TREND STUDY;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; PROGESTINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 84891466356     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078016     Document Type: Article

References (36)

1. Ziel HK, Finkle WD (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293: 1167-1170. doi:10.1056/ NEJM197512042932303. PubMed: 171569.
2. Smith DC, Prentice R, Thompson DJ, Herrmann WL (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293: 1164-1167. doi:10.1056/NEJM197512042932302. PubMed: 1186789.
3. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJ (1981) Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 305: 1599-1605. doi:10.1056/ NEJM198112313052701. PubMed: 7312007.
4. Thom MH, White PJ, Williams RM, Sturdee DW, Paterson ME et al. (1979) Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy. Lancet 2: 455-457. PubMed: 89511.
5. Writing group for the WHI (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the WHI randomized controlled trial. JAMA 88: 321-333
6. Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291: 47-53. doi:10.1001/jama.291.1.47. PubMed: 14709575.
7. von Euler-Chelpin M (2010) Breast cancer incidence and use of hormone therapy in Denmark 1978-2007. Cancer Causes Control.
8. Daubisse-Marliac L, Delafosse P, Boitard JB, Poncet F, Grosclaude P et al. (2011) Breast cancer incidence and time trend in France from 1990 to 2007: a population-based study from two French cancer registries. Ann Oncol 22: 329-334. doi:10.1093/annonc/mdq396. PubMed: 20682549.
9. Fournier A, Kernaleguen C, Panjo H, Clavel-Chapelon F, Ringa V (2011) Postmenopausal hormone therapy initiation before and after the Women's Health Initiative in two French cohorts. Menopause 18: 219-223. PubMed: 21052030.
10. IARC (2012) Monographs on the Evaluation of Carcinogenic Risks to Humans. A Review of Human Carcinogens: Pharmaceuticals, Combined estrogen-progestogen menopausal therapy. IARC Monogr, Volume 100.
11. Collaborative group on hormonal factors in Breast C (1997) Breast cancer and hormonal contraceptive:collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350: 1047-1059
12. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92: 328-332. doi:10.1093/jnci/92.4.328. PubMed: 10675382.
13. Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V et al. (2011) Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 128: 144-156. doi:10.1002/ijc.25314. PubMed: 20232395.
14. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR et al. (2008) Classification and pharmacology of progestins. Maturitas 61: 171-180. doi:10.1016/j.maturitas.2008.11.013. PubMed: 19434889.
15. Beral V, Reeves G, Bull D, Green J (2011) Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy. J Natl Cancer Inst 103: 296-305. doi:10.1093/jnci/djq527. PubMed: 21278356.
16. Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F (2009) Estrogen-Progestagen Menopausal Hormone Therapy and Breast Cancer: Does Delay From Menopause Onset to Treatment Initiation Influence Risks? J Clin Oncol 27: 5138-5143. doi:10.1200/JCO.2008.21.6432. PubMed: 19752341.
17. Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Pettinger M et al. (2008) Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 167: 1207-1216. doi: 10.1093/aje/kwn044. PubMed: 18372396.
18. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F (2005) Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol 96: 95-108. doi:10.1016/j.jsbmb.2005. 02.014. PubMed: 15908197.
19. Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107: 103-111. PubMed: 17333341.
20. Dinger JC, Heinemann LA, Möhner S, Thaid M, Assmann A (2006) Breast cancer risk associated with different HRT formulations: a register-based case-control study. BMC Womens Health 6: 13. doi:10.1186/1472-6874-6-13. PubMed: 16965641.
21. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114: 448-454. doi:10.1002/ijc.20710. PubMed: 15551359.
22. Beral V, Million Women Study C (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419-427. doi:10.1016/S0140-6736(03)14065-2. PubMed: 12927427.
23. Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI (2010) A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. Int J Cancer 126: 483-489. doi:10.1002/ijc.24738. PubMed: 19588504.
24. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N et al. (2008) Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 123: 933-941. doi:10.1002/ijc.23655. PubMed: 18506692.
25. Opatrny L, Dell'Aniello S, Assouline S, Suissa S (2008) Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 115: 169-175. PubMed: 18081598.
26. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE et al. (2012) Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 13: 476-486. doi:10.1016/S1470-2045(12)70075-X. PubMed: 22401913.
27. Kuhl H (2005) Breast cancer risk in the WHI study: the problem of obesity. Maturitas 51: 83-97. doi:10.1016/j.maturitas.2005.02.018. PubMed: 15883113.
28. Allen NE, Tsilidis KK, Key TJ, Dossus L, Kaaks R et al. (2010) Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol 172: 1394-1403. doi:10.1093/aje/kwq300. PubMed: 20961969.
29. Campagnoli C, Abbà C, Ambroggio S, Peris C (2005) Pregnancy, progesterone and progestins in relation to breast cancer risk. J Steroid Biochem Mol Biol 97: 441-450. doi:10.1016/j.jsbmb.2005.08.015. PubMed: 16249080.
30. Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92: 2049-2058. doi:10.1038/sj.bjc.6602617. PubMed: 15900297.
31. Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N et al. (2004) Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109: 721-727. doi:10.1002/ijc.20016. PubMed: 14999781.
32. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT et al. (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289: 3254-3263. doi:10.1001/jama.289.24.3254. PubMed: 12824206.
33. Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F et al. (2008) Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 26: 1260-1268. doi:10.1200/JCO.2007.13.4338. PubMed: 18323549.
34. Reeves GK, Beral V, Green J, Gathani T, Bull D et al. (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7: 910-918. doi:10.1016/S1470-2045(06) 70911-1. PubMed: 17081916.
35. Milanese TR, Hartmann LC, Sellers TA, Frost MH, Vierkant RA et al. (2006) Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 98: 1600-1607. doi:10.1093/jnci/djj439. PubMed: 17105983.
36. Belot A, Grosclaude P, Bossard N, Jougla E (2008) Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 56: 159-175. doi:10.1016/j.respe.2008.03.117. PubMed: 18547762.